Whitney L Do1, Karen Conneely2, Sheryl Gabram-Mendola3, Uma Krishnamurti4, Olivia D'Angelo5, Jasmine Miller-Kleinhenz6, Keerthi Gogineni7, Mylin Torres8, Lauren E McCullough6. 1. Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, 30322, USA. rleet@emory.edu. 2. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA. 3. Department of Surgery, Emory University School of Medicine, Atlanta, GA, 30322, USA. 4. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA. 5. Department of Surgery, Jackson Memorial Hospital/University of Miami Miller School of Medicine, Miami, FL, 33136, USA. 6. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, 30322, USA. 7. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. 8. Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Abstract
PURPOSE: As a primary risk factor and modifier of breast cancer incidence and prognosis, obesity may contribute to race disparities in breast cancer outcomes. This study examined association between obesity and DNA methylation in non-Hispanic Black and White women diagnosed with breast cancer. METHODS: Genome-wide DNA methylation was measured in the breast cancer tumor tissue of 96 women using the EPIC array. To examine the association between obesity and tumor methylation, linear regression models were used-regressing methylation β value for each cytosine and guanine (CpG) site on body mass index adjusting for covariates. Significance was set at false discovery rate (FDR) < 0.05. In the top 20 CpG sites, we explored the interactions with race and estrogen receptor (ER) status. We used multivariable Cox-proportional hazard models to examine whether methylation in the top 20 sites was associated with all-cause mortality. RESULTS: While none of the CpG sites passed the FDR threshold for significance, among the top 20 CpG sites, we observed interactions with race (TOMM20) and ER status (PSMB1, QSOX1 and PHF1). The same CpG sites in TOMM20, PSMB1, and QSOX1 were associated with all-cause mortality. CONCLUSIONS: We identified novel interactions between obesity-associated methylation and both race and ER status in genes that have been associated with tumor regulation. Our data suggest that dysregulation in two sites may associate with all-cause mortality.
PURPOSE: As a primary risk factor and modifier of breast cancer incidence and prognosis, obesity may contribute to race disparities in breast cancer outcomes. This study examined association between obesity and DNA methylation in non-Hispanic Black and White women diagnosed with breast cancer. METHODS: Genome-wide DNA methylation was measured in the breast cancer tumor tissue of 96 women using the EPIC array. To examine the association between obesity and tumor methylation, linear regression models were used-regressing methylation β value for each cytosine and guanine (CpG) site on body mass index adjusting for covariates. Significance was set at false discovery rate (FDR) < 0.05. In the top 20 CpG sites, we explored the interactions with race and estrogen receptor (ER) status. We used multivariable Cox-proportional hazard models to examine whether methylation in the top 20 sites was associated with all-cause mortality. RESULTS: While none of the CpG sites passed the FDR threshold for significance, among the top 20 CpG sites, we observed interactions with race (TOMM20) and ER status (PSMB1, QSOX1 and PHF1). The same CpG sites in TOMM20, PSMB1, and QSOX1 were associated with all-cause mortality. CONCLUSIONS: We identified novel interactions between obesity-associated methylation and both race and ER status in genes that have been associated with tumor regulation. Our data suggest that dysregulation in two sites may associate with all-cause mortality.
Entities:
Keywords:
Breast cancer; Disparity; Epigenetics; Mortality; Obesity
Authors: Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: Elizabeth M Cespedes Feliciano; Marilyn L Kwan; Lawrence H Kushi; Wendy Y Chen; Erin K Weltzien; Adrienne L Castillo; Carol Sweeney; Philip S Bernard; Bette J Caan Journal: Cancer Date: 2017-03-13 Impact factor: 6.860
Authors: Dezheng Huo; Hai Hu; Suhn K Rhie; Eric R Gamazon; Andrew D Cherniack; Jianfang Liu; Toshio F Yoshimatsu; Jason J Pitt; Katherine A Hoadley; Melissa Troester; Yuanbin Ru; Tara Lichtenberg; Lori A Sturtz; Carl S Shelley; Christopher C Benz; Gordon B Mills; Peter W Laird; Craig D Shriver; Charles M Perou; Olufunmilayo I Olopade Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Emily N Devericks; Meredith S Carson; Lauren E McCullough; Michael F Coleman; Stephen D Hursting Journal: Cancer Metastasis Rev Date: 2022-06-25 Impact factor: 9.237